Seeking Alpha
 

Theravance, Inc. (THRX)

- NASDAQ
  • Fri, Feb. 13, 5:36 PM
    • Top gainers, as of 5:15 p.m.: IRWD +5.9%. HK +5.0%. EGY +4.8%. CAG +4.3%. TTS +3.5%.
    • Top losers, as of 5:15 p.m.: PES -9.7%. LOGM -7.7%. HOS -7.2%. THRX -6.4%. BTU -6.3%.
    | 3 Comments
  • Jun. 3, 2014, 12:46 PM
    | 2 Comments
  • May. 6, 2014, 4:55 PM
    • Theravance (THRX): Q1 EPS of -$0.62 misses by $0.11.
    • Revenue of $0.17M (-87.3% Y/Y) misses by $4.35M.
    • Shares +1.18%.
    • Press Release
    | Comment!
  • Nov. 13, 2013, 4:42 PM
    • Theravance (THRX) discloses its TD-9855 drug did not meet the primary efficacy endpoint in Phase 2 study in adult patients with ADHD/hyperactivity disorder and will scrap the program.
    • TD-9855 is still being evaluated in an ongoing Phase 2 study in patients with fibromyalgia; results are anticipated during H1 2014.
    • Shares -3.4% AH.
    | Comment!
  • Sep. 10, 2013, 4:12 PM
    • The FDA'a Pulmonary-Allergy Drugs Advisory Committee votes 11 yes to 2 no that the efficacy and safety data provides substantial evidence to support approval of GlaxoSmithKline's (GSK) and Theravance's (THRX) Ellipta for the maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
    • THRX to resume trading shortly
    | 1 Comment
  • Aug. 1, 2013, 5:20 PM
    • Theravance (THRX) says the FDA's Pulmonary-Allergy Drugs Advisory Committee will discuss the company's NDA for the COPD treatment Anoro Ellipta on September 10. (PR)
    • Shares +1.5% AH.
    | Comment!
  • Jun. 21, 2013, 9:10 AM
    Premarket gainers: SPRD +22%. NVGN +12%. KMX +8%. THRX +7%. MTL +7%.
    Losers: IDIX -35%. ORCL -8%. AHT -5%.
    | Comment!
  • Jun. 17, 2013, 7:17 AM
    Elan (ELN) flies 8.3% premarket after investors approve a $200M share repurchase plan, meaning Royalty Pharma's bid for the company has now lapsed, freeing Elan to seek other buyers. Also rejected is a deal with Theravance (THRX) and the acquisition of AOP Orphan Pharmaceuticals.
    | Comment!
  • Jun. 4, 2013, 2:05 PM
    Institutional Shareholder Services is recommending Elan (ELN +0.6%) shareholders vote against several company proposals - including a $1B royalty-sharing agreement with Theravance (THRX -1.5%) and a $200M stock buyback program at ELN's June 17 special meeting. It withholds recommendation on the Royalty all-cash offer however, although it said voting against ELN's proposals "leaves the door open for shareholders to tender their shares if they so wish."
    | Comment!
  • May. 13, 2013, 9:10 AM
    Premarket gainers: UNIS +25%. SUTR +20%. THRX +13%. PERI +13%. NBG +11%. IGLD +10%. TSLA +6%. CSIQ +5%. SPWR +5%.
    Losers: AFFY -8%. UNXL -5%.
    | Comment!
  • May. 10, 2013, 12:09 PM
    GlaxoSmithKline (GSK +1.5%) and Theravance (THRX +11%) both move higher today after the FDA approves Breo Ellipta for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema. The approval was widely expected after a federal advisory panel endorsed the product last month.
    | Comment!
  • Apr. 26, 2013, 9:11 AM
    Premarket gainers: LOGM +19%. AVNR +16%. SYNA +17%. QLIK +12%. CRIS +9%. DHI +7%. THRX +7%. MUX +7%. JCP +7%. CSTR +6%.
    Losers: PKI -14%. SIMO -11%. BIDU -9%. KEG -8%. SDT -5%
    | Comment!
  • Apr. 25, 2013, 4:48 PM
    Theravance (THRX) races 8% higher in late trading. Concurrently with the release of its Q1 report, THRX announces it intends to split into two independent publicly traded companies. One of the companies will remain focused on "biopharmaceutical operations,"while the other will dedicate itself to managing the "late-stage respiratory assets partnered with GlaxoSmithKline." In other words: THRX is creating a separate company to manage Breo Ellipta/Relvar, the COPD inhaled treatment recently recommended for approval in an FDA panel vote.
    | Comment!
  • Apr. 18, 2013, 9:10 AM
    Premarket gainers: PTGI +33%. THRX +17%. TZOO +11%. ALSN +8%. TSM +7%. MM +6%.
    Losers: EXAS -26%. NOK -11%. UNXL -10%.
    | 1 Comment
  • Apr. 18, 2013, 8:17 AM
    Theravance (THRX) looks poised for a strong session after an FDA advisory panel recommends approval of a once-daily COPD inhaled treatment option (Breo Ellipta) the company is developing with GlaxoSmithKline (GSK). Some color on the story: 1) the drug will be called "Relvar" in the U.S. 2) Annual sales should come in at ~$337M next year. 3) Treatment may be used in conjunction with GSK's $8B per year Advair. 4) Relvar will compete with AstraZeneca's Symbicort which had sales of $3.19B in 2012. THRX shares +16% premarket.
    | 1 Comment
  • Apr. 17, 2013, 7:59 PM
    Shares of Theravance (THRX) soar over 18% in the post-trading session after coming off an all-day trading halt while awaiting the FDA's decision on its COPD inhaler Breo Ellipta. The stock most recently traded at $33.25, after being halted earlier this morning at $28.01, as the FDA voted solidly in favor of approval.
    | Comment!
Visit Seeking Alpha's
THRX vs. ETF Alternatives
Company Description
Theravance Inc., is a biopharmaceutical company with a pipeline of internally discovered product candidates and collaborations with pharmaceutical companies.
Sector: Healthcare
Industry: Biotechnology
Country: United States